Literature DB >> 12296864

Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis.

T A M A Al-Bukhari1, P M Radford, G Bouras, C Davenport, S M Trigwell, G-F Bottazzo, M Lai, H L Schwartz, P J Tighe, I Todd.   

Abstract

Autoantibodies to 65 kDa glutamic acid decarboxylase (GAD65) are produced in many patients with autoimmune polyendocrine syndrome type II (APS-II) or stiff-man syndrome (SMS) and are heterogeneous in their epitope specificities, recognizing both conformational and linear determinants. Major linear epitopes of GAD, which are recognized by autoantibodies in a minority of these patients, occur in the N-terminal and C-terminal regions. We have investigated antibody recognition of the N- and C-termini of GAD65 in relation to their structural features as an approach to understanding what modifications to the native GAD structure may occur that facilitate the generation of antibodies specific to linear epitopes in these regions during the autoimmune pathogenesis. A monoclonal antibody specific to the N-terminus of GAD65 bound both native and denatured GAD in ELISA, whereas monoclonal and polyclonal antibodies specific to the C-terminus of GAD bound only denatured GAD. These antibodies were epitope mapped using random peptide phage-display libraries and the epitopes related to a previously proposed structural model of GAD65. This has led us to propose that the alpha-helical secondary structure of the C-terminus of GAD65 must be denatured to generate linear epitopes. In contrast, the N-terminus is both surface exposed and linear in the native structure, but may be masked by membrane interactions, which must be broken to facilitate recognition by B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12296864      PMCID: PMC1906485          DOI: 10.1046/j.1365-2249.2002.01960.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase.

Authors:  Y C Chang; D I Gottlieb
Journal:  J Neurosci       Date:  1988-06       Impact factor: 6.167

3.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Authors:  S Baekkeskov; H J Aanstoot; S Christgau; A Reetz; M Solimena; M Cascalho; F Folli; H Richter-Olesen; P De Camilli; P D Camilli
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

4.  Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group.

Authors:  P Söhnlein; M Müller; K Syren; U Hartmann; B O Böhm; H M Meinck; M Knip; H K Akerblom; W Richter
Journal:  Diabetologia       Date:  2000-02       Impact factor: 10.122

5.  Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes.

Authors:  E Bonifacio; V Lampasona; L Bernasconi; A G Ziegler
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

6.  Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus.

Authors:  S M Trigwell; P M Radford; S R Page; A C Loweth; R F James; N G Morgan; I Todd
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

7.  Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modeling.

Authors:  M A Myers; J M Davies; J C Tong; J Whisstock; M Scealy; I R Mackay; M J Rowley
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

8.  Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients.

Authors:  L Mauch; C C Abney; H Berg; W A Scherbaum; B Liedvogel; W Northemann
Journal:  Eur J Biochem       Date:  1993-03-01

9.  Monoclonal antibodies specific to the glutamic acid decarboxylase 65 kDa isoform derived from a non-obese diabetic (NOD) mouse.

Authors:  B Ziegler; P Augstein; F Lühder; W Northemann; J Hamann; M Schlosser; I Klöting; D Michaelis; M Ziegler
Journal:  Diabetes Res       Date:  1994

10.  Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus.

Authors:  M Solimena; F Folli; S Denis-Donini; G C Comi; G Pozza; P De Camilli; A M Vicari
Journal:  N Engl J Med       Date:  1988-04-21       Impact factor: 91.245

View more
  9 in total

1.  Post-translational protein modifications in type 1 diabetes: a role for the repair enzyme protein-L-isoaspartate (D-aspartate) O-methyltransferase?

Authors:  A M Wägner; P Cloos; R Bergholdt; P Boissy; T L Andersen; D B Henriksen; C Christiansen; S Christgau; F Pociot; J Nerup
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

2.  Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis.

Authors:  Chiara Zingaretti; Milena Arigò; Angela Cardaci; Monica Moro; Mariacristina Crosti; Antonella Sinisi; Elisa Sugliano; Cristina Cheroni; Francesco Marabita; Renzo Nogarotto; Raoul Jean Pierre Bonnal; Paolo Marcatili; Maurizio Marconi; Annalinda Zignego; Paolo Muratori; Pietro Invernizzi; Piero Colombatto; Maurizia Brunetto; Ferruccio Bonino; Raffaele De Francesco; Jens Geginat; Massimiliano Pagani; Luigi Muratori; Sergio Abrignani; Mauro Bombaci
Journal:  Mol Cell Proteomics       Date:  2012-09-20       Impact factor: 5.911

3.  Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues.

Authors:  Hana Cernecka; Wisuit Pradidarcheep; Wouter H Lamers; Martina Schmidt; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-30       Impact factor: 3.000

4.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

5.  An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Authors:  Bindu Jayakrishnan; David E Hoke; Christopher G Langendorf; Ashley M Buckle; Merrill J Rowley
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

Review 6.  GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions.

Authors:  Popianna Tsiortou; Harry Alexopoulos; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2021-03-30       Impact factor: 6.570

Review 7.  Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-01-27       Impact factor: 6.088

8.  Purification of polyclonal anti-conformational antibodies for use in affinity selection from random peptide phage display libraries: a study using the hydatid vaccine EG95.

Authors:  A J Read; C G Gauci; M W Lightowlers
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-28       Impact factor: 3.205

9.  Mapping of human autoantibody binding sites on the calcium-sensing receptor.

Authors:  E Helen Kemp; Nikos G Gavalas; Samia Akhtar; Kai J E Krohn; J Carl Pallais; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.